查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1462774

癌症疫苗藥物管道市場至2030年的預測：按類型、癌症類型、技術、最終用戶和地區的全球分析

Cancer Vaccines Drug Pipeline Market Forecasts to 2030 - Global Analysis By Type, Cancer Type,Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球癌症疫苗藥物管道市場規模為 64.6 億美元，預計在預測期內將以20.0%的年複合成長率成長，到2030年達到 231.7 億美元。

癌症疫苗藥物管道是指致力於創造疫苗來預防、治療和管理癌症的研究和開發。這些疫苗透過刺激人體的免疫系統識別和攻擊癌細胞來發揮作用，有可能提供一種有針對性的、侵入性較小的癌症治療方法。該管道包括從早期臨床前研究到臨床試驗的各個開發階段，最終目標是將安全有效的癌症疫苗推向市場。

據世界衛生組織（WHO）表示，癌症是全球第二大死亡原因，2018年估計有 960 萬人死亡。

癌症發生率上升

隨著越來越多的人面臨癌症的威脅，對疫苗等有效預防和治療解決方案的需求迅速增加。這種迫切性刺激了研究和開發工作，推動科學家探索、創新和改進疫苗技術，最終擴大研發管道，幫助應對這一日益嚴峻的全球健康挑戰。因此，這些因素加速市場的成長。

複雜的開發流程

許多研發的癌症疫苗在臨床試驗中顯示出有限的功效，引發了人們對其預防和治療癌症有效性的擔憂。此外，對潛在副作用和免疫反應的安全疑慮導致患者和醫療保健專業人員猶豫不決。如此複雜的流程阻礙了一些公司進入市場，並阻礙了管道的整體發展和多元化。

聯合治療

將癌症疫苗與化療、免疫療法和分子標靶療法等其他既定治療方法相結合，為徹底改變癌症治療和改善患者預後提供了獨特的機會。這種方法有可能改善治療結果、最大限度地減少副作用並延長患者的生存期。透過利用各種治療方法的互補作用機制，組合策略解決了癌症的多方面性質，並在持續對抗這種複雜疾病的過程中提供更有效和個性化的方法，目標是為新的治療方法舖平道路。

監管障礙

嚴格的監管要求，包括冗長的核准流程和複雜的臨床試驗通訊協定，可能會延遲市場進入並增加開發成本。不斷變化的監管指南和嚴格的安全標準的不確定性可能會限制對癌症疫苗研發的投資。此外，不同地區和司法管轄區不同的監管標準可能會使市場狀況更加複雜，並限制進入全球市場。

COVID-19 的影響

COVID-19 大流行轉移了癌症研究和開發的資源、注意力和資金，減緩了疫苗發現和臨床試驗的進展。封鎖措施擾亂了供應鏈，停止了臨床試驗，並減緩了潛在癌症疫苗的進展。儘管遇到這些挫折，疫情仍然刺激了疫苗開發的創新和合作，加速了遠端醫療和遠距臨床試驗監測的採用。

預計預防性疫苗領域在預測期內將是最大的。

預計預防性疫苗領域將佔據最大佔有率。預防性疫苗的重點是透過針對已知會導致某些類型癌症的特定感染因子來預防癌症的發展。這些疫苗的作用是刺激免疫系統識別和消滅與癌症發展相關的病原體，例如病毒和細菌。此外，透過預防這些致癌性病原體的感染，預防性疫苗目的是降低相關癌症的風險。

預計肺癌領域在預測期內年複合成長率最高

預計肺癌領域在預測期內將出現良好的成長。該領域致力於開發專門用於預防或治療肺癌的疫苗。這些疫苗針對肺癌細胞上的抗原，目的是觸發人體針對癌細胞的免疫反應。肺癌是一個重要的全球健康議題，開發有效的疫苗有望減輕肺癌的負擔，並提高病患的存活率。

佔有率最大的地區

由於癌症盛行率上升以及人們認知的提高和預防措施的採用增加，亞太地區在預測期內佔據了最大的市場佔有率。由於人口眾多、生技產業的成長以及有利的監管政策，中國成為最大的市場。許多亞洲國家的法律規範變得更加精簡和高效，促進了新癌症疫苗的開發和核准。此外，該地區各國政府積極支持癌症研究和開發，包括資助疫苗開發和臨床試驗。

年複合成長率最高的地區：

預計北美在預測期內將實現盈利成長。北美的癌症負擔很高，全部區域流行多種類型的癌症。因此，對有效的預防和治療方法的需求日益成長。該地區也是積極致力於開發創新癌症疫苗的主要研究機構、製藥公司和生物技術公司的所在地。政府機構和私人投資者都為癌症研究和開發（包括疫苗計畫）的資金籌措做出了重大貢獻。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球癌症疫苗藥物管道市場：依類型

  • 預防性疫苗
  • 治療性疫苗

第6章 全球癌症疫苗藥物管道市場：依癌症類型分類

  • 乳癌
  • 攝護腺癌
  • 肺癌
  • 大腸直腸癌
  • 其他癌症類型

第7章 全球癌症疫苗藥物管道市場：依技術分類

  • 重組疫苗
  • 病毒載體疫苗
  • 全細胞疫苗
  • DNA疫苗
  • 其他技術

第8章 全球癌症疫苗藥物管道市場：依最終用戶分類

  • 醫院
  • 門診治療中心

第9章 全球癌症疫苗藥物管道市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東、非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • AstraZeneca
  • F. Hoffmann-La Roche
  • Merck & Co.
  • Pfizer
  • Johnson & Johnson
  • Sanofi
  • GlaxoSmithKline（GSK）
  • Moderna
  • Novartis
  • Bristol-Myers Squibb
  • BioNTech
  • Genentech
  • Bavarian Nordic
  • Takeda Pharmaceuticals
  • OncoGenex Pharmaceuticals
  • Northwest Biotherapeutics
  • Vaxil Bio
  • Immunomic Therapeutics
  • Transgene
  • Arbor Pharmaceuticals
Product Code: SMRC25825

According to Stratistics MRC, the Global Cancer Vaccines Drug Pipeline Market is accounted for $6.46 billion in 2023 and is expected to reach $23.17 billion by 2030 growing at a CAGR of 20.0% during the forecast period. The Cancer Vaccines Drug Pipeline is the ongoing research and development efforts focused on creating vaccines for preventing, treating, or managing cancer. These vaccines work by stimulating the body's immune system to recognize and attack cancer cells, offering a potentially targeted and less invasive approach to cancer treatment. The pipeline includes various stages of development, from early preclinical research to clinical trials, with the ultimate goal of bringing safe and effective cancer vaccines to market.

According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, responsible for an estimated 9.6 million deaths in 2018.

Market Dynamics:

Driver:

Rising incidence of cancer

As more individuals face the threat of cancer, the demand for effective preventative and therapeutic solutions like vaccines surges. This urgency incentivizes research and development efforts, pushing scientists to explore, innovate, and refine vaccine technologies, ultimately expanding the pipeline with the hope of combating this growing global health challenge. Therefore, these factors are accelerating market growth.

Restraint:

Complex development process

Many cancer vaccines in the pipeline demonstrate limited efficacy in clinical trials, raising concerns about their effectiveness in preventing or treating cancer. Also, safety concerns regarding potential side effects and immune reactions can create hesitancy among patients and healthcare professionals. The complex process discourages some companies from entering the market, hindering the overall development and diversification of the pipeline.

Opportunity:

Combination therapies

Integrating cancer vaccines with other established therapies, such as chemotherapy, immunotherapy, or targeted therapies, presents a unique opportunity to revolutionize cancer treatment and improve patient outcomes. This approach holds promise for improving treatment outcomes, minimising adverse effects, and potentially extending patient survival. By leveraging the complementary mechanisms of action of various therapies, combination strategies aim to address the multifaceted nature of cancer, paving the way for more effective and personalised treatment approaches in the ongoing battle against this complex disease.

Threat:

Regulatory hurdles

Stringent regulatory requirements, including lengthy approval processes and complex clinical trial protocols, can delay market entry and increase development costs. Uncertainty surrounding evolving regulatory guidelines and stringent safety standards may deter investment in cancer vaccine research and development. Also, varying regulatory standards across different regions and jurisdictions further complicate the market landscape, potentially limiting global market access.

Covid-19 Impact

The COVID-19 pandemic has diverted resources, attention, and funding away from cancer research and development, slowing down progress in vaccine discovery and clinical trials. Lockdown measures disrupted supply chains and halted clinical trials, delaying the advancement of potential cancer vaccines. Despite these setbacks, the pandemic has also spurred innovation and collaboration in vaccine development, leading to the accelerated adoption of telemedicine and remote clinical trial monitoring, which may benefit the cancer vaccine pipeline market in the long term.

The prophylactic vaccine segment is expected to be the largest during the forecast period

The prophylactic vaccine segment is estimated to hold the largest share. The prophylactic vaccine focuses on preventing the development of cancer by targeting specific infectious agents known to cause certain types of cancer. These vaccines work by stimulating the immune system to recognise and destroy pathogens, such as viruses or bacteria that are linked to cancer development. Moreover, by preventing infection with these carcinogenic agents, prophylactic vaccines aim to reduce the risk of developing associated cancers.

The lung cancer segment is expected to have the highest CAGR during the forecast period

The lung cancer segment is anticipated to have lucrative growth during the forecast period. This segment focuses on the development of vaccines specifically designed to prevent or treat lung cancer. These vaccines target antigens present in lung cancer cells, aiming to trigger the body's immune response against tumour cells. With lung cancer being a significant global health concern, the development of effective vaccines holds promise for reducing its burden and improving patient survival rates.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to the rising prevalence of cancer in the region, coupled with increasing awareness and adoption of preventive measures. China is the largest market, driven by its large population, growing biotechnology sector, and favourable regulatory policies. Regulatory frameworks in many Asian countries are becoming more streamlined and efficient, facilitating the development and approval of new cancer vaccines. Moreover, governments in the region are actively supporting cancer research and development, including funding for vaccine development and clinical trials.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America faces a significant burden of cancer, with several types prevalent across the region. This drives demand for effective preventive and therapeutic options. Also, the region boasts leading research institutions, pharmaceutical companies, and biotechnology firms actively engaged in developing innovative cancer vaccines. Both government agencies and private investors significantly contribute to funding cancer research and development, including vaccine programs.

Key players in the market

Some of the key players in the Cancer Vaccines Drug Pipeline Market include AstraZeneca, F. Hoffmann-La Roche, Merck & Co., Pfizer, Johnson & Johnson, Sanofi, GlaxoSmithKline (GSK), Moderna, Novartis, Bristol-Myers Squibb, BioNTech, Genentech, Bavarian Nordic, Takeda Pharmaceuticals, OncoGenex Pharmaceuticals, Northwest Biotherapeutics, Vaxil Bio, Immunomic Therapeutics, Transgene and Arbor Pharmaceuticals.

Key Developments:

In February 2024, AstraZeneca unveils successes in treatment of lung cancer, with its leading drug slowing progression of the disease at an early stage. AstraZeneca also announced that the drug had been approved to be used alongside chemotherapy in the US to treat the same form of lung cancer at an advanced stage, where it extended progression-free survival by almost nine months.

In December 2023, AstraZeneca ties up with AI Biologics Company to develop cancer drug. The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy - a leading focus of Anglo-Swedish drugmaker AstraZeneca.

Types Covered:

  • Prophylactic Vaccine
  • Therapeutic Vaccine

Cancer Types Covered:

  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Other Cancer Types

Technologies Covered:

  • Recombinant Vaccines
  • Viral Vector Vaccines
  • Whole-Cell Vaccines
  • DNA Vaccines
  • Other Technologies

End Users Covered:

  • Hospital
  • Ambulatory Care Centers

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Vaccines Drug Pipeline Market, By Type

  • 5.1 Introduction
  • 5.2 Prophylactic Vaccine
  • 5.3 Therapeutic Vaccine

6 Global Cancer Vaccines Drug Pipeline Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 Breast Cancer
  • 6.3 Prostate Cancer
  • 6.4 Lung Cancer
  • 6.5 Colorectal Cancer
  • 6.6 Other Cancer Types

7 Global Cancer Vaccines Drug Pipeline Market, By Technology

  • 7.1 Introduction
  • 7.2 Recombinant Vaccines
  • 7.3 Viral Vector Vaccines
  • 7.4 Whole-Cell Vaccines
  • 7.5 DNA Vaccines
  • 7.6 Other Technologies

8 Global Cancer Vaccines Drug Pipeline Market, By End User

  • 8.1 Introduction
  • 8.2 Hospital
  • 8.3 Ambulatory Care Centers

9 Global Cancer Vaccines Drug Pipeline Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AstraZeneca
  • 11.2 F. Hoffmann-La Roche
  • 11.3 Merck & Co.
  • 11.4 Pfizer
  • 11.5 Johnson & Johnson
  • 11.6 Sanofi
  • 11.7 GlaxoSmithKline (GSK)
  • 11.8 Moderna
  • 11.9 Novartis
  • 11.10 Bristol-Myers Squibb
  • 11.11 BioNTech
  • 11.12 Genentech
  • 11.13 Bavarian Nordic
  • 11.14 Takeda Pharmaceuticals
  • 11.15 OncoGenex Pharmaceuticals
  • 11.16 Northwest Biotherapeutics
  • 11.17 Vaxil Bio
  • 11.18 Immunomic Therapeutics
  • 11.19 Transgene
  • 11.20 Arbor Pharmaceuticals

List of Tables

  • Table 1 Global Cancer Vaccines Drug Pipeline Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
  • Table 4 Global Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
  • Table 5 Global Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 6 Global Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 7 Global Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 8 Global Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 9 Global Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 10 Global Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 11 Global Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
  • Table 12 Global Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 13 Global Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 14 Global Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
  • Table 15 Global Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
  • Table 16 Global Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 17 Global Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
  • Table 18 Global Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 19 Global Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 20 North America Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
  • Table 22 North America Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
  • Table 23 North America Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
  • Table 24 North America Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 25 North America Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 26 North America Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 27 North America Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 28 North America Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 29 North America Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 30 North America Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
  • Table 31 North America Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 32 North America Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 33 North America Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
  • Table 34 North America Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
  • Table 35 North America Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 36 North America Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
  • Table 37 North America Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 38 North America Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 39 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
  • Table 41 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
  • Table 42 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
  • Table 43 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 44 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 45 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 46 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 47 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 48 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 49 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
  • Table 50 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 51 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 52 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
  • Table 53 Europe Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
  • Table 54 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 55 Europe Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
  • Table 56 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 57 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 58 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
  • Table 60 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
  • Table 61 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
  • Table 62 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 63 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 64 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 65 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 66 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 67 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 68 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
  • Table 69 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 70 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 71 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
  • Table 72 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
  • Table 73 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 74 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
  • Table 75 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 76 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 77 South America Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
  • Table 79 South America Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
  • Table 80 South America Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
  • Table 81 South America Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 82 South America Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 83 South America Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 84 South America Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 85 South America Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 86 South America Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 87 South America Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
  • Table 88 South America Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 89 South America Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 90 South America Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
  • Table 91 South America Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
  • Table 92 South America Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 93 South America Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
  • Table 94 South America Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 95 South America Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
  • Table 96 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
  • Table 98 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
  • Table 99 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
  • Table 100 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 101 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 102 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 103 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 104 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 105 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 106 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
  • Table 107 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 108 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 109 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
  • Table 110 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
  • Table 111 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 112 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
  • Table 113 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
  • Table 114 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)